Jeffrey Yordon

Insider Reports History

Entity
Individual
Signature
/s/Staci Holquist, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jeffrey Yordon:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Athenex, Inc. COO, and President, Athenex Pharmaceutical Division. Common Stock 246K $334K $1.36 Aug 3, 2022 Direct
Athenex, Inc. COO, and President, Athenex Pharmaceutical Division. Stock Option (Right to Buy) 150K Aug 3, 2022 Direct
Athenex, Inc. COO, and President, Athenex Pharmaceutical Division. Restricted Stock Units 37.5K Aug 3, 2022 Direct

Insider Reports Filed by Jeffrey Yordon

Symbol Company Period Transactions Value $ Form Type Date Filed Role
ATNXQ Athenex, Inc. Aug 3, 2022 3 -$2.13K 4 Aug 15, 2022 COO, and President, Athenex Pharmaceutical Division.
ATNXQ Athenex, Inc. Jul 20, 2022 1 $0 4 Jul 21, 2022 COO, and President, Athenex Pharmaceutical Division. Exhibit List: Exhibit 24.1 - Power of Attorney
ATNXQ Athenex, Inc. Aug 3, 2021 2 $0 4 Aug 5, 2021 COO, and President, Athenex Pharmaceutical Division.